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Abstract
Background: LIM and SH3 protein 1 (LASP-1), initially identified from human breast cancer, is a specific focal
adhesion protein involved in cell proliferation and migration, which was reported to be overexpressed in 8–12 %
of human breast cancers and thought to be exclusively located in cytoplasm.
Methods: In the present work we analyzed the cellular and histological expression pattern of LASP-1 and its
involvement in biological behavior of human breast cancer through correlation with standard clinicopathological
parameters and expression of c-erbB2 (HER-2/neu), estrogen- (ER) and progesterone-receptors (PR). For this
purpose immunohistochemical staining intensity and percentage of stained cells were semi-quantitatively rated to
define a LASP-1 immunoreactive score (LASP-1-IRS). LASP-1-IRS was determined in 83 cases of invasive ductal
breast carcinomas, 25 ductal carcinomas in situ (DCIS) and 18 fibroadenomas. Cellular LASP-1 distribution and
expression pattern was visualized by immunofluorescence and confocal microscopy and assessed through
separate Western blots of nuclear and cytosol preparations of BT-20, MCF-7, MDA-MB231, and ZR-75/1 breast
cancer cells.
Results: Statistical analysis revealed that the resulting LASP-1-IRS was significantly higher in invasive carcinomas
compared to fibroadenomas (p = 0.0176). Strong cytoplasmatic expression of LASP-1 was detected in 55.4 % of
the invasive carcinomas, which correlated significantly with nuclear LASP-1-positivity (p = 0.0014), increased
tumor size (p = 0.0159) and rate of nodal-positivity (p = 0.0066). However, levels of LASP-1 expression did not
correlate with average age at time point of diagnosis, histological tumor grading, c-erbB2-, ER- or PR-expression.
Increased nuclear localization and cytosolic expression of LASP-1 was found in breast cancer with higher tumor
stage as well as in rapidly proliferating epidermal basal cells. Confocal microscopy and separate Western blots of
cytosolic and nuclear preparations confirmed nuclear localization of LASP-1.
Conclusion: The current data provide evidence that LASP-1 is not exclusively a cytosolic protein, but is also
detectable within the nucleus. Increased expression of LASP-1 in vivo is present in breast carcinomas with higher
tumor stage and therefore may be related with worse prognosis concerning patients' overall survival.
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Background
Breast cancer is the most frequent malignancy among
women and ranks first as cause of cancer deaths among
women at ages between 20 to 59 years [1]. Despite the use
of endocrine therapy, systemic chemotherapy and novel
approaches such as treatment with trastuzumab (Hercep-
tin®), outcome of metastatic breast cancer has not substan-
tially improved. Metastatic disease remains generally
incurable with a median survival time of only a few years
[2,3]. Thus, new therapeutic modalities are required to
improve the outcome. Genes that are overexpressed in
metastatic cancer cells are promising targets for novel
therapeutic agents.
The LIM and SH3 domain protein LASP-1 was initially
identified from a cDNA library of breast cancer metas-
tases. The gene was mapped to human chromosome
17q21 in a region that is altered in 20–30% of human
breast cancers [4,5], suggesting that it could play a role in
tumor development and metastases of breast cancer.
Human LASP-1 encodes a membrane-bound protein of
261 amino acids containing one N-terminal LIM domain,
followed by two actin-binding sites and a C-terminal src
homology SH3 domain. The actin-binding domains in
the core of LASP-1 mediate an interaction between LASP-
1 and actin at cell membrane extensions, but not along
actin stress fibers [6-10].
Recent data showed an additional interaction of LASP-1
via its nebulin like actin-binding repeats with kelch
related protein 1 (Krp1), a focal adhesion protein
involved in cell migration. The exact cellular function of
LASP-1 is not known yet, but the protein has previously
been reported to localize within multiple sites of dynamic
actin assembly such as focal contacts, focal adhesions,
lamellipodia, membrane ruffles and pseudopodia
[4,7,11-13].
The C-terminal SH3 domain of LASP-1 is involved in pro-
tein-protein interactions through binding to proline-rich
sequences, specifically with zyxin, palladin, lipoma pre-
ferred partner (LPP) and vasodilator stimulated phospho-
protein (VASP) [9,14,15]. Mutation analysis of LASP-1 led
to the conclusion that its SH3 domain is necessary for
pseudopodial extension and invasion [16].
Although no binding partner for the LIM domain of LASP-
1 has been identified so far, previous data have shown
that the zinc-finger module in the LIM domain of LASP-1
is an morphologically and perhaps functionally inde-
pendent folding-unit of this protein harboring the possi-
bility of direct binding to DNA [17].
Moreover, LASP-1 is substrate of Abelson tyrosine kinase.
Abelson tyrosine kinase is strongly involved in carcino-
genesis of hematopoetic tumors, such as B-cell lympho-
mas [18]. Phosphorylation of LASP-1 at tyrosine 171 is
associated with loss of LASP-1 from focal adhesion points
and the initiation of cell death, but without changes in
dynamics of migratory processes [13]. In addition, phos-
phorylation of LASP-1 at serine 146 by cAMP- and cGMP-
dependent protein kinases resulted in a translocation of
the protein from membrane to cytosol and was followed
by reduced cell migration [8]. All these protein-protein
interactions mediated by the LIM and SH3 domains can
be regarded as scaffolds for the formation of higher order
complexes and suggest that LASP-1 could be part of
important signaling pathways and a structural protein as
well.
LASP-1 expression has been reported to be increased in
metastatic breast cancer, suggesting that overexpression of
LASP-1 may be involved in the migratory process of these
cells [4]. Interestingly, knock-down of LASP-1 by RNA-
interference in metastatic breast cancer cell lines BT-20
and MCF-7, as well as in the ovarian cancer cell line
SKOV-3 resulted in a strong inhibition of proliferation,
migration and in cell cycle arrest in G2-phase without
induction of apoptosis or necrosis. Furthermore, LASP-1
silencing was accompanied by a reduced binding of the
LASP-1 binding partner zyxin to focal contacts.
Reversely, artificial overexpression of LASP-1 in non-neo-
plastic PTK2 (Potorous tridactylis kidney) cells hardly
expressing endogenous LASP-1, resulted in a acceleration
of migration [19,20].
In this study we demonstrate that LASP-1 is not only a
cytosolic, but also a nuclear located protein, which is
highly overexpressed in breast cancer tissue compared to
benign fibroadenomas. Furthermore, we provide evidence
that its cytosolic overexpression and nuclear localization
correlates significantly with tumor size and nodal-positiv-
ity of human breast carcinomas.
Methods
Tissue samples
The studies were performed with approval of the Ethics
Committee of the University of Wuerzburg. Paraffin
embedded tissue samples of 126 archival cases with con-
firmed histological diagnosis were obtained from the
department of Pathology of the University of Wuerzburg.
We analyzed 25 cases of ductal carcinoma in situ without
any invasive component (DCIS), 83 invasive ductal breast
carcinomas and 18 fibroadenomas as well as three sam-
ples of normal breast tissue from reduction mammo-
plasty.BMC Cancer 2007, 7:198 http://www.biomedcentral.com/1471-2407/7/198
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The patients with invasive breast carcinomas were aged
from 32 to 96 (mean 58.6 ± 13.52) years. In this study all
carcinomas, which were mainly collected from patients
undergoing wide excisions, have been classified according
to criteria of the WHO and recorded as invasive ductal car-
cinomas by a pathologist. Grading of malignancy of duc-
tal carcinomas was evaluated according to the Scarff,
Bloom and Richardson criteria with guidelines as sug-
gested by Nottingham City Hospital Pathologists [21].
Tumor staging was performed according to parameters of
the TNM system [22].
Immunohistochemistry
For immunohistochemical staining procedures tissue sec-
tions were cut from regular paraffin embedded tissue at 2–
3 µm. Sections were placed onto APES (3-amino-propyl-
triethoxy-silane; Roth, Karlsruhe, Germany) coated slides,
dewaxed in xylene, rehydrated in graded ethanol and in
TRIS-buffered saline (TBS; 25 mM TRIS/HCl, pH 7.4, 137
mM NaCl, 2.7 mM KCl). For antigen retrieval, sections
were subjected to heat pretreatment by boiling it in 0.01
M of sodium citrate buffer (pH 6.0) for 10 min in a micro-
wave oven (600Watt/sec.). Endogenous peroxidase was
blocked by incubation in 0.1% hydrogen peroxide in PBS
for 5 min. Slides were then incubated with the polyclonal
anti-LASP-1 antibody [8] diluted 1:1000 in "antibody
diluent" (DAKO, Hamburg, Germany) followed by EnVi-
sion/rabbit detection system (DAKO, Hamburg, Ger-
many). 3,3'-Diaminobenzidine (DAB; DAKO, Hamburg,
Germany) was used as chromogen and sections were
counterstained in hematoxylin (Mayers, Sigma, Deisen-
hofen, Germany), dehydrated through graded ethanol
and embedded in Entelan (Merck, Darmstadt, Germany).
Evaluation of immunohistochemical LASP-1 staining and 
LASP-1-IRS
To assess the role of LASP-1 in human breast cancer, we
examined its expression in 83 breast carcinoma samples
from patients selected randomly from January 2000 to
December 2006 with or without invasive components.
Semi-quantitative evaluation of LASP-1 immunostaining
was carried out by three independent observers (TG, UK
and EB) through defining of the percentage of positive
cells and the staining intensity as described below. In
most of all cases (> 90%) the independently determined
LASP-1-IRS was consistent within all observers. In the rare
event of divergent evaluation, a consensus was found. For
positive controls we used breast cancer sections previously
described as highly LASP-1-positive [19]. In negative con-
trols with omitted primary antibody or with pre-immune
serum no staining was observed.
Scoring of cytosolic LASP-1 expression was carried out in
analogy to scoring of hormone receptor Immune Reactive
Score (IRS) ranging from 0–12 according to Remmele et
al. [23], which is used routinely in surgical pathology for
the quantification of hormone receptor expression in
mammary carcinoma.
The percentage of LASP-1-postitive stained cells was
scored in five grades (grade 0 = 0–19%, grade 1 = 20–39%,
grade 2 = 40–59%, grade 1 = 60–79% and grade 4 = 80–
100% LASP-1 expressing tumor cells). The fraction of
LASP-1-positive stained cells was scored after having
examined 10 high-power fields (40×) of one section for
each sample. In addition, the intensity of LASP-1 expres-
sion by the tumor cells was determined (grade 0 = none,
grade 1 = low, grade 2 = moderate, grade 3 = strong). The
multiplication of these two grading scores calculates the
immunoreactive score for LASP-1 expression (LASP-1-
IRS) in stained tissue (% LASP-1-positive tumor cells ×
staining intensity = LASP-1-IRS). Examples for the very
heterogeneous LASP-1 expression in invasive breast can-
cer are given in Figure 1.
For better statistical discrimination samples scored with
cytosolic LASP-1-IRS < 5 were classified as LASP-1-nega-
tive, those with LASP-1-IRS > 5 or higher as LASP-1-posi-
tive.
Nuclear LASP-1-positivity was scored by determining per-
centage of positive nuclei regardless of cytosolic LASP-1
expression and staining intensity. In analogy to the scor-
ing of the proliferation marker Ki67 samples were consid-
ered as nuclear-positive (NUC+) if 10% or more cells
showed nuclear staining for LASP-1 [24].
Heterogeneous LASP-1 expression in human invasive breast  cancer Figure 1
Heterogeneous LASP-1 expression in human invasive 
breast cancer. Immunohistochemical staining of different 
LASP-1 expression intensity levels in human invasive breast 
cancer samples (DAB, brown; magnification 100×). (A+B) 
low LASP-1-IRS (< 5). (C+D) medium to high LASP-1-IRS (> 
5).BMC Cancer 2007, 7:198 http://www.biomedcentral.com/1471-2407/7/198
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The immunomarkers c-erbB2 (HER-2/neu), estrogen
receptor (ER) and progesterone receptor (PR) assessed in
this study had been previously detected by standard
immunohistochemistry and were drawn from the archival
database of the Department of Pathology, Wuerzburg.
Statistical analysis
Graph Pad Prism software test statistics was used to assess
LASP-1 expression and the categorical parameters of inter-
est. Furthermore, multivariate non-parametric analysis
was performed using Fisher's exact (F) and Mann-Whitney
(M) test. In the statistical analysis invasive ductal carcino-
mas were sorted in groups depending on nodal-positive
or nodal-negative status and small (T1 = ∅ max. 2 cm) or
larger tumor size (> T1). This dichotomous graduation
was made on the basis of a recent meta-analysis stating
that the most beneficial prognostic criteria are nodal-neg-
ativity and a small tumor size at time point of diagnosis
[25].
Further stratification of our tumor samples according to
extent of nodal positivity and advanced tumor size was
abandoned, since there are no additional major therapeu-
tic implications [26].
Cell culture conditions
Cell lines (MCF-7, BT-20, MDA-MB231 and ZR-75/1)
were obtained from Cell Line Services (Heidelberg, Ger-
many) and grown at 1 × 105 cells/ml in a plastic cell cul-
ture flask in a humidified incubator at 37°C under 5%
CO2 atmosphere in HBCA-medium [27] containing 10%
heat-inactivated fetal bovine serum (PAA, Linz, Austria)
and 1% streptomycin/ampicillin (Invitrogen, Karlsruhe,
Germany). Cells were cultured until homogeneous mor-
phology of cells was reached (passage 3–4) since LASP-1
belongs to a group of several differential expressed pro-
teins that are up-regulated after later passages [28].
Immunofluorescence and confocal imaging
For confocal microscopy, cells were grown until homoge-
nous morphology at a maximum of 70% confluence on
glass chamber slides, fixed in 4% (w/v) paraformaldehyde
in PBS, permeabilized with 0.1% (w/v) Triton X-100 in
PBS, and then stained with affinity-purified LASP-1 anti-
body (1:2000) followed by secondary Cy3-labeled anti-
rabbit antibody (1:500) (Dianova, Hamburg, Germany).
Fluorescence and transmission-DIC images were recorded
on a modified confocal microscope (Leica SP5, Man-
nheim, Germany) with a 100× NA 1.4 objective (Leica,
Wetzlar, Germany). Fluorescence was detected with SP5
spectral emission setting at 570–650 nm for the Cy3 and
with the DIC-transmission channel. The images were
recorded with 512 × 512 pixels with lateral resolution
between 90 and 200 nm and a recording rate of 400 lines
per second. Each image was also line averaged 4 times and
the entire frame was averaged twice for optimal signal to
noise ratio. The images were converted to .tiff format and
analyzed with Photoshop™ software.
Preparation of nuclear and cytosolic cell fractions
Human breast cancer cell lines were harvested at 80% con-
fluence through trypsination. Isolation of nuclei and
cytosol was carried out using NE-PER Nuclear and Cyto-
plasmic Extraction Reagents (Pierce, Bonn, Germany) fol-
lowing the manufacturers instructions. Probes were
solved in Laemmli sample buffer at a final concentration
of 1 × 106 /ml and stored at -20°C before Western Blot
electrophoresis.
Western blot analysis
For Western blotting cells were lysed in Laemmli sample
buffer. Equal amounts of protein, according to cell count,
were resolved by 12% SDS-PAGE. After blotting on nitro-
cellulose membrane and blocking with 3% nonfat dry
milk in 10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% (w/v)
Tween 20, the membrane was first incubated with the
antibody raised against LASP-1 (1:10000) [8] followed by
incubation with horseradish peroxidase-coupled goat
anti-rabbit IgG (Biorad, Munich, Germany), diluted
1:5000, and visualization was done using ECL (Amer-
sham Biosciences, Freiburg, Germany). Protein bands
were visualized by autoradiography. Quantification of
autoradiography signals was carried out by densitometry
using the ImageJ software (NIH, Bethesda, USA).
GAPDH was used as a specific cytosolic marker to exclude
cytoplasmatic contamination of the nuclei preparation
and was visualized by incubating NC membrane with pol-
yclonal anti-GAPDH primary antibody (1:1000; Santa
Cruz, Santa Cruz, USA). Anti Lamin A+C antibody (1: 50;
Abcam, Cambridge, UK) served as a specific nuclear
marker to exclude nuclear contamination in cytoplas-
matic cell samples [29-31]. At least three independent
experiments have been carried out and representative
results are shown.
Results
LASP-1 is overexpressed in invasive breast cancer tissue
LASP-1 expression was detected in cytoplasm of tumor
cells, leukocytes, myoepithelial cells and vascular smooth
muscle cells, but not in stromal cells. Immunohistochem-
istry clearly allowed to localize LASP-1 expression in car-
cinoma cells of 76 malignant breast carcinomas (91.56
%), whereas in seven patients LASP-1 could not be
detected in invasive neoplastic cells. Medium to high
LASP-1-IRS (>5) was observed in 46 cases (55.4%), which
were considered to be LASP-1-positive, while 37 probes
(44.6%) showed a low LASP-1-IRS (<5) and were consid-
ered to be LASP-1-negative (Table 1 and Figure 2B). InBMC Cancer 2007, 7:198 http://www.biomedcentral.com/1471-2407/7/198
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contrast, LASP-1 could not be detected in benign epithe-
lial cells of reduction mammoplasty.
In analogy to previous findings in myoepithelial and vas-
cular smooth muscle cells of human breast and ovarian
tissue [19,20], LASP-1 overexpression could be observed
in highly proliferating epidermal basal cells (Figure 3A),
while cells of non-proliferating superficial layers or der-
mal connective tissue cells like fibroblasts showed only
weak LASP-1 expression. Interestingly, strong nuclear
LASP-1-positivity could be observed in about 29% of all
breast carcinomas as well as in nuclei of epidermal basal
cells (Figures 3A, 3B and 3C), whereas all other breast car-
cinoma nuclei were negative for LASP-1 and the cells only
displayed perinuclear and cytosolic LASP-1 enrichment
(Figure 3D).
In 89% of all tumor-samples, which were scored to be
LASP-1-negative, LASP-1 was not detectable within the
nucleus, while 43.5% of all LASP-1-positive specimens
showed clear nuclear LASP-1 staining. Thus nuclear stain-
Histological expression pattern of LASP-1 Figure 3
Histological expression pattern of LASP-1. Immunohis-
tochemical staining of LASP-1 (DAB, brown, magnification 
100×) in different cell types. White arrows indicate LASP-1-
negative nuclei, black arrows LASP-1-positive nuclei. (A) 
LASP-1 is highly overexpressed in physiologically proliferating 
epidermal basal cells, compared to superficial epidermal 
strata or dermal connective tissue cells. (B+C) LASP-1 is 
localized abundantly in nuclei of invasive breast cancer cells 
compared to LASP-1-negative nuclei of stromal cells. (D) 
Invasive breast cancer cells with LASP-1-negative nuclei but 
perinuclear and cytosolic LASP-1 overexpression. (E) 
Nuclear and cytosolic LASP-1-positive breast cancer cells in 
direct neighborhood to infiltrating LASP-1-negative lym-
phocytes.
Table 1: Statistical analysis of LASP-1 expression in 83 breast cancer samples (in-CA), 25 ductal carcinomas in situ (DCIS) and 18 
fibroadenomas (FIBRO). IRS: immune reactive score; n.s.: not significant
LASP-1 + LASP-1 - IRS mean IRS STDV IRS Median p-values (Fisher's exact)
n% n %
FIBRO 4 22.2 14 77.8 3.11 2.22 3 0.7315 n.s. 0.0176*
DCIS 8 32 17 68 3.48 2.80 3 0.7315 n.s. 0.066 n.s. 0.0176*
in-CA 46 55.4 37 44.6 5.75 3.73 8 0.066 n.s. 0.0176*
Graphical illustration of statistical LASP-1 distribution Figure 2
Graphical illustration of statistical LASP-1 distribu-
tion. (A) LASP-1-IRS (immunoreactive score) is significantly 
higher in invasive breast carcinomas (in-Ca) compared to 
fibroadenomas (Fibro). Error bars represent standard devia-
tion. (B) Distribution of LASP-1-positivity (L+) and LASP-1-
negativity (L-) in fibroadenomas, DCIS and invasive breast 
cancer. (C+D) Positive nodal status (N+) and tumor size 
(>T1) correlate significantly with LASP-1-positivity. Signifi-
cant statistical differences are labeled with one star (p < 0.05) 
or two stars (p < 0.01).BMC Cancer 2007, 7:198 http://www.biomedcentral.com/1471-2407/7/198
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ing is correlated with cytosolic LASP-1 expression and sig-
nificantly higher in LASP-1-positive cells compared to
LASP-1-negative samples (p = 0.0014; Table 2).
However, two samples (2.4%) showed a very high nuclear
LASP-1-positivity with concurrent low cytosolic staining
(Figure 3B).
This nuclear staining is unlikely to be unspecific, because
nuclei of other benign stromal cells like fibrocytes are
LASP-1-negative, even when located right next to cancer
cells (Figures 3B and 3C).
This observation is even more obvious in Figure 3E, show-
ing strong LASP-1-positive nuclei and cytosol of human
breast cancer cells in comparison to LASP-1-negative
nuclei of neighboring infiltrating lymphocytes.
LASP-1 expression is significantly higher in invasive breast 
cancer compared to fibroadenomas and is correlated with 
TNM-staging
Comparison of average LASP-1 expression of fibroadeno-
mas, DCIS and invasive breast cancer demonstrated that
invasive cancer cells display significantly higher LASP-1
expression than fibroadenomas (p = 0.0176), as seen in
Table 1 and Figure 2A. In contrast, staining intensity of
LASP-1 in DCIS was not significantly higher than in
fibroadenomas, but also not significantly lower than in
invasive breast cancer (Table 1 and Figures 2A and 2B).
To evaluate the clinical relevance of the heterogeneous
LASP-1 expression, LASP-1-IRS was compared to clinico-
pathological and biological parameters. Positive correla-
tions were found between LASP-1-IRS and TNM-staging
regarding tumor size T (p = 0.0159) and nodal-positivity
(p = 0.0066; Table 2) (Figures 2C and 2D). No correlation
was found with age at time of surgery (Table 3), grading,
ER- and PR-positivity and HER-2/neu-expression (Table
2).
To evaluate the possible relevance of LASP-1 as a prognos-
tic marker for lymph node metastasis in human breast
cancer disease, a contingency test was performed and
prognostic indices were calculated. Sensitivity of LASP-1-
IRS-scoring to predict node-positivity is 85% with a specif-
icity of 36.4%, (positive and negative predictive value
73.9 vs. 51.3%, respectively).
LASP-1 is detectable within the nucleus by confocal 
microscopy
To further assess the cellular expression pattern of LASP-1,
we performed confocal and non-confocal microscopy of
immunofluorescence labeled LASP-1 in the breast cancer
cell line BT-20. The immunofluorescence images showed
a variable cellular expression pattern of the protein. In
addition to the reported localization of LASP-1 (white
arrows) to focal contacts and tips of lamellipodia (Figure
4A) [4,7,11-13], LASP-1 was detected in the cytosol (Fig-
ure 4C), perinuclear (Figures 4B and 4D) and nuclear (Fig-
ures 4B and 4E). This is in accordance to the LASP-1
localization observed in the breast tissue samples (Figure
3). A similar immunohistochemical staining pattern was
detected in MCF-7 breast cancer cells and SKOV-3 ovarian
cancer cells (data not shown).
LASP-1 is detectable in nuclear fractions of various breast 
cancer cell lines by Western blotting
To verify the nuclear localization of LASP-1, MCF-7, BT-
20, MDA-MB231 and ZR-75/1 breast cancer cells were
separated in cytosolic and nuclear fractions and assessed
by Western blot. Equal amounts of protein, according to
Table 3: Statistical analysis of LASP-1 (L) expression in relation 
to age. FIBRO: fibroadenome (n = 18); DCIS: ductal carcinomas 
in situ (n = 25); in-CA: invasive breast cancer (n = 83).
FIBRO DCIS in-CA
L  +L  - L  +L  - L  +L  -
Age (yrs) mean 40.8 40 54.1 54.5 61.1 55.1
STDEV 8.9 16.1 11.6 13.7 13.7 11.9
Table 2: Statistical analysis of LASP-1 distribution and expression 
in correlation to clinicopathological and biological parameters. 
LASP-1 (L) protein expression was analyzed in 83 breast cancer 
samples. Associations with clinicopathological and biological 
parameters were analyzed using Mann-Whitney-test (M) and 










Nodal status N+ 50 60.2 34 73.9 16 43.2 0.0066 (F)
N- 33 39.9 12 26.1 21 56.8 **
Tumor size T1 39 47 16 34.8 23 62.2 0.0159 (F)
> T 1 4 45 33 0 6 5 . 2 1 4 3 7 . 8 *
Grading G1 3 3.6 0 0 3 8.1 0.9593 (M)
G2 39 47 24 52.2 15 40.5 n.s.
G3 41 49.4 22 47.8 19 51.4
c-erB-2 Her+ 18 21.7 12 26.1 6 16.2 0.3005 (F)
Her- 65 78.3 34 73.9 31 83.8 n.s.
Estrogen 
receptor
ER+ 60 72.3 33 71.7 27 73 1.0 (F)
ER- 23 27.7 13 28.3 10 27 n.s.
Progesterone 
receptor
PR+ 51 61.5 26 56.5 25 67.6 0.3673 (F)





24 29 20 43.5 4 11 0.0014 (F)
NUC- 59 71 26 56.5 33 89 **BMC Cancer 2007, 7:198 http://www.biomedcentral.com/1471-2407/7/198
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cell count, were resolved by 12% SDS-PAGE and blotted
on nitrocellulose membrane. As seen in Figure 5, LASP-1
is clearly detectable in the nuclei of human breast cancer
cell lines MCF-7 and BT-20, while nuclei of MDA-MB231
and ZR-75/1 cells were found to be negative for LASP-1 in
the nuclear fraction. GAPDH was used as a specific
cytosolic marker to exclude cytoplasmatic contamination
of nuclei samples during preparation. Reversely Lamin
A+C served as a specific nuclear marker to exclude nuclear
contamination in cytoplasmatic cell fractions (Figure 5).
Discussion
In the present work we investigated for the first time the
expression of LASP-1 in a series of 83 invasive breast car-
cinomas at protein level and compared the data to clini-
cally established breast cancer parameters. We found that
the degree of immunohistochemical staining correlated
significantly with nodal metastasis and tumor size but
seems to be independent of other parameters such as age,
grading and estrogen or progesterone receptor status.
In contrast to earlier publications, demonstrating the co-
amplification of the LASP-1 gene together with HER-2/
neu (c-erbB2) [4,32], our statistical analysis revealed no
relation between LASP-1 protein level and HER-2/neu
protein expression.
A previous study also showed that LASP-1 mRNA is over-
expressed in only 8–12% of all human breast cancers [5].
However, our immunohistochemical analysis provide evi-
dence that the LIM and SH3 domain protein is highly
expressed (LASP-1-positive) in 55.4% of all tested breast
cancer samples. This discrepancy could be due to the fact
that Tomasetto et al. [4] used total surgical specimens for
their mRNA isolation, containing undefined amounts of
LASP-1 free benign tissue, while our data focused on
malign cells only.
Consistent with the high expression of LASP-1 in breast
tumors recent data demonstrated the functional signifi-
cance of LASP-1 for cancer metastasis. Silencing of LASP-1
by RNAi in highly LASP-1 expressing human breast and
ovarian cancer cells led to reduced cell proliferation,
migration and to cell cycle arrest in G2-phase [19,20].
These experiments are supported by our present study
proving the significantly higher expression of LASP-1 in
invasive breast carcinomas compared to benign fibroade-
nomas. The rate of strongly LASP-1 expressing samples of
invasive ductal carcinomas amounted 55.4% (LASP-1-IRS
> 5). Moreover, statistical analysis provided evidence for a
positive correlation of cytosolic as well as nuclear LASP-1-
positivity with tumor size and nodal-positivity indicating
an important role of LASP-1 in proliferation and migra-
tion.
These data resemble those of another focal adhesion pro-
tein, ENAH. ENAH is a member of the ENAH/VASP pro-
tein family, which regulates cell migration and actin-
cytoskeleton organization at focal contacts. Like LASP-1,
ENAH is not detectable in benign breast epithelium, but
is weakly expressed in low-risk benign diseases like
fibroadenomas and strongly expressed in invasive breast
Western Blot of nuclear and cytosolic fractions of the cancer  cell lines MCF-7, BT-20, MDA-MB231 and ZR-75/1 Figure 5
Western Blot of nuclear and cytosolic fractions of the 
cancer cell lines MCF-7, BT-20, MDA-MB231 and ZR-
75/1. LASP-1 is detectable in nuclear (N) as well as in cyto-
plasmatic (C) cell fractions of breast cell lines MCF-7 and BT-
20, but not in the nucleus of MDA-MB231 and ZR-75/1 cells. 
GAPDH was used as a cytoplasmatic marker, Lamin A + C as 
nuclear markers to exclude contamination during cell frac-
tion isolation.
Cellular LASP-1 expression pattern visualized by confocal  microscopy Figure 4
Cellular LASP-1 expression pattern visualized by 
confocal microscopy. Non-confocal (A+B) and confocal 
(C-E) microscopy of LASP-1 immunostaining in BT-20 breast 
cancer cells revealed that LASP-1 (red) is mainly detectable 
in focal contacts (A) and in the cytosol (C). In addition, more 
than 30% of the cells show a nuclear staining (B+E), and in 
some cells a perinuclear localization of LASP-1 is visible 
(B+D).BMC Cancer 2007, 7:198 http://www.biomedcentral.com/1471-2407/7/198
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cancers. Similar to LASP-1, there is a significant correla-
tion of ENAH-expression and tumor size (p < 0.05) [33].
In contrast to LASP-1, siRNA induced ENAH-knock-down
does not affect cell proliferation while LASP-1 silencing
resulted in strong inhibition of cell growth and migration
[19]. Thus, it is likely that among several focal adhesion
proteins which are overexpressed in breast cancer LASP-1
has more regulative function than others.
In a recent investigation, a cDNA microarray was used to
establish a prognostic index for nodal-positive breast can-
cer [34]. Similar to our study, all 20 patients were LASP-1-
positive, albeit LASP-1 was found to be one out of five
genes being under-expressed in patients that died within
5 years after surgery. This is in part differing from our
results demonstrating a correlation between high LASP-1
protein levels and nodal-positivity. However, in many
cases there are significant discrepancies between the meas-
ured mRNA levels and protein data indicating post-tran-
scriptional mechanism of regulation and stabilization
[35].
In the present work we provide evidence for LASP-1 being
not only a cytosolic, but also a nuclear protein. By our
immunohistochemical stainings LASP-1 was detectable in
nuclei of 29% of all investigated breast carcinomas inde-
pendent of its actual cytosolic expression. Images taken
with confocal microscopy confirmed nuclear localization
of LASP-1 within the nucleus in BT-20 and MCF-7 breast
cancer cells. Although these monoclonal cell lines are
genetically identical, immunostaining demonstrated a
variable cytosolic and nuclear LASP-1 localization, possi-
bly dependent on cell cycle. Western blot analysis verified
nuclear LASP-1 localization in MCF-7 and BT-20 cells
while breast cancer cell lines MDA-MB231 and ZR-75/1
only displayed a cytosolic but no nuclear LASP-1 localiza-
tion. Cell line ZR-75/1 is known to be highly estrogen and
progesterone dependent [36] and was found to have the
highest c-erbB2-expression among eight characterized
breast- and four ovarian-cancer cell lines [37], whereas
MDA-MB231 cells are ER- and PR-receptor negative and
express HER-2/neu only at very low levels [38]. However,
in our study LASP-1-IRS as well as nuclear LASP-1-positiv-
ity did not correlate with ER-, PR- or HER-2/neu-expres-
sion.
Previous data have shown that the zinc-finger containing
LIM domain of LASP-1 is a morphologically and perhaps
functionally independent folding-unit offering the possi-
bility of direct binding to DNA [17]. In general, LIM
domains are specialized double zinc-finger motifs inter-
acting with many different proteins in association with
the cytoskeleton and even form homeodomains to
become nuclear transcription factors [39,40]. No hetero-
or homodimerization of LASP-1 has been reported yet [9].
However, LASP-1 binding partner zyxin is a LIM domain
containing protein known to be a nuclear shuttle protein
involved in cell migration and cell cycle control [41,42],
which could act as a potential interaction partner of LASP-
1 in cell core.
In our present study we could demonstrate that LASP-1 is
not only highly expressed in fast proliferating malignant
tumor cells, but also in proliferating regenerative epider-
mal basal cells, while slowly proliferating dermal fibrob-
lasts are LASP-1-negative. This observation is consistent
with previous findings showing that LASP-1 expression
positively influences tumor cell proliferation [19,20].
However, preliminary results show no correlation
between the well-known proliferation marker Ki67 and
LASP-1 expression (data not shown). Nevertheless, previ-
ous publications have shown that Ki67 expression is often
considered as false positive and is inferior in evaluating
tumor proliferation activity compared to standardized
mitotic index at optimal cut-off points. This implies that
evaluation of patients' prognosis by Ki67 expression has
to be appraised with caution [43].
Further statistical calculations with contingency tests
demonstrated that according to our data, postoperative
relevance of LASP-1 expression for prediction of nodal-
positivity has a sensitivity of about 85%, suggesting that
LASP-1 could be used as a predictive marker for lymph
node metastasis together with other markers like the supe-
rior method of sentinel lymph node biopsy with an aver-
age sensitivity of about 95% [44]. Thus postoperative
non-invasive LASP-1 scoring in primary tumor tissue
could accomplish node-positivity prediction as an addi-
tional marker to invasive sentinel node biopsy, especially
in cases of negative sentinel node biopsy or if patients
reject invasive sentinel node biopsy.
Conclusion
This study is the first description of LASP-1 as a nuclear
protein, whose cytosolic expression and nuclear localiza-
tion correlates in vivo with tumor size and nodal positiv-
ity of human invasive ductal carcinoma of the breast. In
summary, our observations suggest an expanded role for
LASP-1 in biological breast cancer behavior. Further pro-
spective studies will be necessary to define the potential of
LASP-1 as an independent marker for diagnosis of cancer
as well as a marker for prognosis of this disease.
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